P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2023-01, Vol.17 (Supplement_1), p.i507-i508
Main Authors: Sands, B E, Jain, A, Ahmad, H A, Osterman, M, Memaj, A, Canavan, J B, Axelrad, J E
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page i508
container_issue Supplement_1
container_start_page i507
container_title Journal of Crohn's and colitis
container_volume 17
creator Sands, B E
Jain, A
Ahmad, H A
Osterman, M
Memaj, A
Canavan, J B
Axelrad, J E
description
doi_str_mv 10.1093/ecco-jcc/jjac190.0506
format article
fullrecord <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ecco_jcc_jjac190_0506</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_ecco_jcc_jjac190_0506</sourcerecordid><originalsourceid>FETCH-LOGICAL-c936-c2c24b62fe2200ea14846478b6a03936f70b84e86751f6e9a55b22d707823a073</originalsourceid><addsrcrecordid>eNotkMtOwzAQRS0EEqXwCUjzA2kd27FjdqgqD6kCFt1HjjNWHaVxFKeF9OtJoau5Gp17F4eQx5QuUqr5Eq0NSW3tsq6NTTVd0IzKKzJLcyUTIZS-_ss80VrIW3IXY01ppjOVz8j4xZWEtXPeGjtCcBBOpvX7UIFv4YhVaPzpsDdlgj9diFhBZwaP7RDh2w87ODQW--lzRLATOvj4BAa6nYkIHLb9AeEj9BM4lQfYBQumNc0YfbwnN840ER8ud062L-vt6i3ZfL6-r543idVcJpZZJkrJHDJGKZpU5EIKlZfSUD4BTtEyF5hLlaVOojZZVjJWKapyxg1VfE6y_1nbhxh7dEXX-73pxyKlxVlfcdZXTPqKi77irI__Arq1Z3s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis</title><source>Oxford Journals Online</source><creator>Sands, B E ; Jain, A ; Ahmad, H A ; Osterman, M ; Memaj, A ; Canavan, J B ; Axelrad, J E</creator><creatorcontrib>Sands, B E ; Jain, A ; Ahmad, H A ; Osterman, M ; Memaj, A ; Canavan, J B ; Axelrad, J E</creatorcontrib><identifier>ISSN: 1873-9946</identifier><identifier>EISSN: 1876-4479</identifier><identifier>DOI: 10.1093/ecco-jcc/jjac190.0506</identifier><language>eng</language><ispartof>Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i507-i508</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Sands, B E</creatorcontrib><creatorcontrib>Jain, A</creatorcontrib><creatorcontrib>Ahmad, H A</creatorcontrib><creatorcontrib>Osterman, M</creatorcontrib><creatorcontrib>Memaj, A</creatorcontrib><creatorcontrib>Canavan, J B</creatorcontrib><creatorcontrib>Axelrad, J E</creatorcontrib><title>P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis</title><title>Journal of Crohn's and colitis</title><issn>1873-9946</issn><issn>1876-4479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkMtOwzAQRS0EEqXwCUjzA2kd27FjdqgqD6kCFt1HjjNWHaVxFKeF9OtJoau5Gp17F4eQx5QuUqr5Eq0NSW3tsq6NTTVd0IzKKzJLcyUTIZS-_ss80VrIW3IXY01ppjOVz8j4xZWEtXPeGjtCcBBOpvX7UIFv4YhVaPzpsDdlgj9diFhBZwaP7RDh2w87ODQW--lzRLATOvj4BAa6nYkIHLb9AeEj9BM4lQfYBQumNc0YfbwnN840ER8ud062L-vt6i3ZfL6-r543idVcJpZZJkrJHDJGKZpU5EIKlZfSUD4BTtEyF5hLlaVOojZZVjJWKapyxg1VfE6y_1nbhxh7dEXX-73pxyKlxVlfcdZXTPqKi77irI__Arq1Z3s</recordid><startdate>20230130</startdate><enddate>20230130</enddate><creator>Sands, B E</creator><creator>Jain, A</creator><creator>Ahmad, H A</creator><creator>Osterman, M</creator><creator>Memaj, A</creator><creator>Canavan, J B</creator><creator>Axelrad, J E</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230130</creationdate><title>P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis</title><author>Sands, B E ; Jain, A ; Ahmad, H A ; Osterman, M ; Memaj, A ; Canavan, J B ; Axelrad, J E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c936-c2c24b62fe2200ea14846478b6a03936f70b84e86751f6e9a55b22d707823a073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sands, B E</creatorcontrib><creatorcontrib>Jain, A</creatorcontrib><creatorcontrib>Ahmad, H A</creatorcontrib><creatorcontrib>Osterman, M</creatorcontrib><creatorcontrib>Memaj, A</creatorcontrib><creatorcontrib>Canavan, J B</creatorcontrib><creatorcontrib>Axelrad, J E</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of Crohn's and colitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sands, B E</au><au>Jain, A</au><au>Ahmad, H A</au><au>Osterman, M</au><au>Memaj, A</au><au>Canavan, J B</au><au>Axelrad, J E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis</atitle><jtitle>Journal of Crohn's and colitis</jtitle><date>2023-01-30</date><risdate>2023</risdate><volume>17</volume><issue>Supplement_1</issue><spage>i507</spage><epage>i508</epage><pages>i507-i508</pages><issn>1873-9946</issn><eissn>1876-4479</eissn><doi>10.1093/ecco-jcc/jjac190.0506</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1873-9946
ispartof Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i507-i508
issn 1873-9946
1876-4479
language eng
recordid cdi_crossref_primary_10_1093_ecco_jcc_jjac190_0506
source Oxford Journals Online
title P376 Efficacy of ozanimod in vedolizumab-exposed patients with ulcerative colitis: a phase 3 True North post hoc analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T02%3A16%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=P376%20Efficacy%20of%20ozanimod%20in%20vedolizumab-exposed%20patients%20with%20ulcerative%20colitis:%20a%20phase%203%20True%20North%20post%20hoc%20analysis&rft.jtitle=Journal%20of%20Crohn's%20and%20colitis&rft.au=Sands,%20B%20E&rft.date=2023-01-30&rft.volume=17&rft.issue=Supplement_1&rft.spage=i507&rft.epage=i508&rft.pages=i507-i508&rft.issn=1873-9946&rft.eissn=1876-4479&rft_id=info:doi/10.1093/ecco-jcc/jjac190.0506&rft_dat=%3Ccrossref%3E10_1093_ecco_jcc_jjac190_0506%3C/crossref%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c936-c2c24b62fe2200ea14846478b6a03936f70b84e86751f6e9a55b22d707823a073%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true